Search research articles
Contact Us
Filters
Showing results (231-240 of 330) with videos related to
Page
of 33
Sort By:
Neuro-Oncology
|
August 10, 2022
A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics
Priya U Kumthekar, Michael J Avram, Andrew B Lassman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 19, 2022
Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Kala Visvanathan, Leslie Cope, Mary Jo Fackler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 19, 2008
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer
Nancy U Lin, Lisa A Carey, Minetta C Liu, et al.
Breast Cancer Research and Treatment
|
November 8, 2013
A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases
Nancy U Lin, Rachel A Freedman, Naren Ramakrishna, et al.
Cancer
|
December 8, 2020
Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial
Jose P Leone, Bernard F Cole, Meredith M Regan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 25, 2020
Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study
Ines Vaz-Luis, Romualdo Barroso-Sousa, Antonio Di Meglio, et al.
Nature Medicine
|
September 13, 2024
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial
Nadia Harbeck, Eva Ciruelos, Guy Jerusalem, et al.
JAMA Oncology
|
September 4, 2020
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial
Sara M Tolaney, Romualdo Barroso-Sousa, Tanya Keenan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2016
Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study
Kala Visvanathan, MaryJo S Fackler, Zhe Zhang, et al.
Nature Communications
|
May 31, 2022
STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer
Qiwei Wang, Johann S Bergholz, Liya Ding, et al.
Page
of 33
Search research articles
Search
Showing results (231-240 of 330) with videos related to
Sort By:
Page
of 33
Neuro-Oncology
|
August 10, 2022
A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics
Priya U Kumthekar, Michael J Avram, Andrew B Lassman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 19, 2022
Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Kala Visvanathan, Leslie Cope, Mary Jo Fackler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 19, 2008
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer
Nancy U Lin, Lisa A Carey, Minetta C Liu, et al.
Breast Cancer Research and Treatment
|
November 8, 2013
A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases
Nancy U Lin, Rachel A Freedman, Naren Ramakrishna, et al.
Cancer
|
December 8, 2020
Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial
Jose P Leone, Bernard F Cole, Meredith M Regan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 25, 2020
Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study
Ines Vaz-Luis, Romualdo Barroso-Sousa, Antonio Di Meglio, et al.
Nature Medicine
|
September 13, 2024
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial
Nadia Harbeck, Eva Ciruelos, Guy Jerusalem, et al.
JAMA Oncology
|
September 4, 2020
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial
Sara M Tolaney, Romualdo Barroso-Sousa, Tanya Keenan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2016
Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study
Kala Visvanathan, MaryJo S Fackler, Zhe Zhang, et al.
Nature Communications
|
May 31, 2022
STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer
Qiwei Wang, Johann S Bergholz, Liya Ding, et al.
Page
of 33